Improved survival after allogeneic hematopoietic cell transplantation (allo-HCT) enables us to learn more about potential late complications after HCT, one of which is metabolic syndrome. There are no studies investigating the prevalence or development of metabolic syndrome within the first year post-HCT in adult myeloablative transplant recipients.
Methods:
In this retrospective study, we evaluated the prevalence of and risk factors associated with metabolic syndrome early post-HCT in human subjects. Due to lack of complete information regarding all the factors that define metabolic syndrome, we evaluated metabolic characteristics using available objective data referred to as modified metabolic syndrome (MMS). The cohort included 785 patients.
Results:
We demonstrated that the incidence of MMS was 34% pre-HCT, 48% at day 80 post-HCT, and 40% at 1 year post-HCT. MMS at day 80 post-HCT was predictive of having MMS at 1 year post-HCT.
Conclusion:
These results support the need for nutrition and lifestyle intervention to prevent and treat metabolic abnormalities among patients who survive the acute transplant period.
Get full access to this article
View all access options for this article.
References
1.
GooleyTA, ChienJW, PergamSA, et al.Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med, 2010; 363:2091–2101.
2.
MajhailNS, FlowersME, NessKK, et al.High prevalence of metabolic syndrome after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant, 2009; 43:49–54.
3.
AnnaloroC, UsardiP, AiraghiL, et al.Prevalence of metabolic syndrome in long-term survivors of hematopoietic stem cell transplantation. Bone Marrow Transplant, 2008; 41:797–804.
4.
RoziakováL, BojtárováE, MistríkM, et al.The late effects in patients treated with allogeneic hematopoietic stem cell transplantation. Klin Onkol, 2011; 24:453–459.
5.
ParisC, YatesL, LamaP, et al.Evaluation of metabolic syndrome after hematopoietic stem cell transplantation in children and adolescents. Pediatr Blood Cancer, 2012; 59:306–310.
6.
EckelRH, AlbertiKG, GrundySM, et al.The metabolic syndrome. Lancet, 2010; 375:181–183.
7.
GrundySM, BrewerHBJr, CleemanJI, et al.Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Associate conference on scientific issues related to definition. Circulation, 2004; 109:433–438.
8.
Lamon-FavaS, WilsonPW, SchaeferEJ. Impact of body mass index on coronary heart disease risk factors in men and women. The Framingham offspring study. Arterioscler Thromb Vasc Biol, 1996; 16:1509–1515.
9.
CraigSR, AminRV, RussellDW, et al.Blood cholesterol screening influence of fasting state on cholesterol results and management decisions. J Gen Intern Med, 2000; 15:395–399.
10.
GenuthS, AlbertiKG, BennettP, et al.Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care, 2003; 26:3160–3167.
11.
FordES, GilesWH, DietzWH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA, 2002; 287:356–359.
12.
GamiAS, WittBJ, HowardDE, et al.Metabolic syndrome and risk of incident cardiovascular events and death: A systemic review and meta-analysis of longitudinal studies. J Am Coll Cardiol, 2007; 49:403–414.
13.
BakerKS, ChowE, SteinbergerJ. Metabolic syndrome and cardiovascular risk in survivors after hematopoietic cell transplantation. Bone Marrow Transplant, 2012; 47:619–625.
14.
BakerKS, NessKK, SteinbergerJ, et al.Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: A report from the bone marrow transplantation survivor study. Blood, 2007; 109:1765–1772.
15.
MajhailNS, ChallaTR, MulrooneyDA, et al.Hypertension and diabetes mellitus in adult and pediatric survivors of allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant, 2009; 15:1100–1107.
16.
SternJM, BruemmerB, MoinpourCM, et al.Impact of a randomized, controlled trial of liberal vs conservative hospital discharge on energy, protein, and fluid intake in patients who received marrow transplants. J Am Diet Assoc, 2000; 100:1015–1022.
17.
CharuhasPM, FosbergKL, BruemmerB, et al.A double-blind randomized trial comparing outpatient parenteral nutrition with intravenous hydration: Effect on resumption of oral intake after marrow transplantation. JPEN, 1997; 21:157–161.
18.
VisschersRG, Olde DaminkSW, GehlenJM, et al.Treatment of hypertriglyceridemia in patients receiving parenteral nutrition. JPEN, 2011; 35:610–615.
19.
AltabasV. Drug treatment of metabolic syndrome. Curr Clin Pharmacol, 2013; 8:224–231.
20.
AppelLJ, MooreTJ, ObarzanekEV, et al.A clinical trial of the effects of dietary patterns on blood pressure. N Engl J Med, 1997; 336:1117–1124.
21.
CampbellKL, Van PattenCL, NeilSE, et al.Feasibility of a lifestyle intervention on body weight and serum biomarkers in breast cancer survivors with overweight and obesity. J Acad Nutr Diet, 2012; 112:559–567.
22.
CottellKE, DorfmanLR, StraightCR, et al.The effects of diet education plus light resistance training on coronary heart disease risk factors in community-dwelling older adults. J Nutr Health Aging, 2011; 15:762–767.
23.
BarrattR, FrostG, MillwardDJ, et al.A randomised controlled trial investigating the effect of an intensive lifestyle intervention v. standard care in adults with type 2 diabetes immediately after initiating insulin therapy. Br J Nutr, 2008; 99:1025–1031.
24.
Salehi-AbargoueiA, MaghsoudiZ, ShiraniF, et al.Effects of Dietary Approaches to Stop Hypertension (DASH)-style diet on fatal or nonfatal cardiovascular diseases-Incidence: A systematic review and meta-analysis on observational prospective studies. Nutrition, 2013; 29:611–618.
